Nationwide Newborn Screening for Mucopolysaccharidoses in Taiwan: Impact, Early Diagnosis, and Clinical Advances over the Past Decade
Screening newborns for four rare storage diseases in Taiwan caught all 31 cases before symptoms appeared, enabling immediate treatment.
Taiwan's national NBS program screened over 838,000 infants for MPS I, II, IVA, and VI using LC-MS/MS enzyme activity from dried blood spots, identifying 31 confirmed cases — all asymptomatic at diagnosis — reducing diagnostic age by >95% (from 4.3yr to 0.2yr). The program enabled early initiation of disease-specific therapies and identified novel MPS-related variants in the Taiwanese population.
What the study was
- Study design
- Population-based NBS program evaluation (retrospective cohort)
- Population
- Newborns in Taiwan screened for MPS I, II, IVA, VI (2015–2025)
- Sample size
- 838585
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Genetics in Medicine
Why it surfaced
Large-scale NBS validation (n=838,585) with 10-year outcomes demonstrating strong reduction in diagnostic delay for rare fatal lysosomal storage disorders. Near-term implementable as a model for other national programs. Validated evidence category given decade of program data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.